A personal COVID-19 dendritic cell vaccine made at point-of-care: Feasibility, safety, and antigen-specific cellular immune responses

• Ngā kaituhi matua: Gabriel I. Nistor (Author), Robert O. Dillman (Author), Rockelle M. Robles (Author), James L. Langford (Author), Aleksandra J. Poole (Author), Muchlis A. U. Sofro (Author), Yetty M. Nency (Author), Jonny Jonny (Author), Martina L. Yana (Author), Mahammad Karyana (Author), Endang S. Lestari (Author), Ria Triwardhani (Author), Mujahidah Mujahidah (Author), Retty K. Sari (Author), Nur A. Soetojo (Author), Djoko Wibisono (Author), Daniel Tjen (Author), Taruna Ikrar (Author), Gregory Sarkissian (Author), Haryono Winarta (Author), Terawan A. Putranto (Author), Hans S. Keirstead (Author)
• Hōputu: Pukapuka
• I whakaputaina: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Ngā marau: article
• Urunga tuihono: Connect to this object online.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish the feasibility of personal dendritic cell vaccines...